Latest news with #Coeptis
Business Insider
24-07-2025
- Business
- Business Insider
Coeptis Announces Merger with Z Squared, Marking Strategic Pivot into Dogecoin Mining
Former biotech company moves to capitalize on altcoin infrastructure, led by Dogecoin-focused mining operations. Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has entered into a definitive agreement to merge with Z Squared, a digital asset mining company focused on Dogecoin (DOGE) and other altcoins. The transaction marks a significant change in direction for Coeptis, which is shifting away from its biopharmaceutical business to focus fully on the cryptocurrency mining sector. As part of the deal, Coeptis will acquire Z Squared's large-scale mining operation, including hardware valued at approximately $660 million, hosting agreements across multiple jurisdictions, and proprietary software systems designed to manage energy use and optimize performance in real time. Dogecoin plays a central role in this pivot. Once known mostly for its origins as a joke, DOGE has since become one of the most visible cryptocurrencies, with a market cap of more than $20 billion and a global user base that remains highly active. For COEP, this visibility—and the volatility that comes with it—offers a chance to participate in an altcoin segment that has often remained out of reach for public market investors. A Shift from Biotech to Blockchain Coeptis plans to spin off its biopharma assets into a separate company, allowing its public-facing entity to focus entirely on digital asset infrastructure. Leadership of the combined business will include David Halabu as Chief Executive Officer and Michelle Burke as Chief Operating Officer. Burke, who previously served as COO of Minting Dome Inc., brings experience in managing international mining logistics and hardware deployment. That experience will be key as the company works across different energy markets and regulatory environments. Z Squared's mining strategy is built around flexibility. Rather than relying on a single facility, it partners with hosting providers in multiple regions to take advantage of favorable electricity pricing and local policy conditions. The company's real-time analytics engine helps it adapt to changing power markets by continuously reallocating hash power and managing power curtailment as needed. Opening a New Lane in Public Markets This merger creates a new option for public investors interested in altcoin infrastructure. While most publicly traded mining companies are focused almost entirely on Bitcoin, COEP's entry into Dogecoin and Litecoin mining offers a different kind of exposure. It's a niche that has drawn growing interest, but until now has had limited availability in the public market. Z Squared has also taken steps to address operational pressure points. The company has built internal logistics and repair capabilities that help reduce equipment downtime and extend the lifespan of mining rigs. This approach lowers capital costs and creates a more durable infrastructure in a competitive space where margins can shift quickly. With this merger, COEP is positioning itself to serve a part of the crypto ecosystem that continues to grow in relevance but has been underserved by public market offerings. The move is both a break from its past and a bet on where digital infrastructure is headed next. About Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) is a biopharmaceutical and technology company advancing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its pipeline includes clinical-stage and preclinical assets, such as DVX201 and SNAP-CAR, licensed from Deverra Therapeutics and the University of Pittsburgh. In parallel, Coeptis has established a Technology Division focused on operational enhancement through AI-powered marketing and automation tools. Headquartered in Wexford, PA, the company is currently transitioning its business model through a proposed merger with Z Squared to enter the digital asset mining sector. Contact
Business Journals
28-04-2025
- Business
- Business Journals
Coeptis to acquire Dogecoin miner Z Squared
Story Highlights Coeptis Therapeutics will merge with Z Squared, a Dogecoin mining company. Coeptis will spin off its biopharmaceutical operations into a separate company. David Halabu will become CEO of the new Dogecoin-focused company. Wexford-based company Coeptis Inc. will merge with a digital mining company and spin off its biopharmaceutical operations into a separate company after the deal is complete. The merger agreement calls for Coeptis to acquire Z Squared Inc., a Dogecoin mining company with Z Squared shareholders receiving Coeptis equity in exchange for 9,000 Dogecoin (DOGE) mining machines. That will lead Coeptis to spin out its biopharmaceuticals into a separate and unrelated company and the remaining company will be known as Z Squared Inc. and focus on mining Dogecoin and other digital assets. 'We are excited to take this step towards our goal of creating the largest publicly traded company in the United States primarily focused on Doge mining,' said David Halabu, CEO of Z Squared who will become CEO of the newly created company. The new company also plans to be listed on the Nasdaq capital market. Coeptis, which was founded in 2017 to develop cell therapies to treat CD38-type cancers, went public Oct. 31, 2021, when it completed a special acquisition corporation merger with Bull Horn Acquisition Corp. The company has been developing those technologies while also working in other areas, including a rebranding in January as Coeptis that involved blockchain and AI after the company did a reverse stock split in December and regained more than $1 a share to remain on the Nasdaq stock exchange. Dogecoin is an open-source peer-to-peer digital currency that employs blockchain technology. It was created by two software engineers in 2013 by what the Dogecoin website calls an 'accidental crypto-movement.' The market value as of Monday is 18 cents per Dogecoin. That's up from 0.0025 in May 2020, according to Google Finance. "We're proud of our strategy to bring retail and institutional audiences alike in the public markets a focused exposure to a DOGE asset that currently has over $20B in market capitalization,' said Halabu. "We believe we have assembled a stellar team that has the requisite expertise and infrastructure." Also part of the executive team will be Michelle Burke, who had been CEO of digital asset miner Minting Dome, as COO. Coeptis President/CEO Dave Mehalick will be leaving the new company's board of directors when the deal closes. "We are excited to bring this opportunity to our shareholders to become involved in the Dogecoin market space, while at the same time being able to remain involved in our biopharmaceutical operations as a result of the contemplated spin out of those operations at closing," Mehalick said in a statement. "I've been deeply engaged in the evolution of blockchain infrastructure and am aligned with the direction the new leadership intends to take the Company." Coeptis has grown over the last several years, licensing cell therapies from Devarra Therapeutics in 2023 and reaching licensing agreements in 2022 and 2023 with the University of Pittsburgh over technology platforms that develop treatments with cancer. The first, reached in May 2022, focuses on SNAP-CAR-T cells that target multiple antigens within the body. The second agreement in October 2023 extended the partnership to include a platform that will help develop NK, or natural killer, cells to treat cancers. It also launched an innovation arm named GEAR Therapeutics in March.
Globe and Mail
14-03-2025
- Business
- Globe and Mail
Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License
COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative oncology solutions, making it an attractive opportunity for traders and investors looking for high-growth potential in the biotech sector. What Makes GEAR-NK a Game-Changer? GEAR-NK (Gene-Edited Antibody Resistant Natural Killer Cells) represents a first-in-class approach to optimizing cancer immunotherapy. Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion. This advancement allows for a synergistic effect, enhancing the potency and efficacy of combination cancer treatments. By integrating GEAR technology into hematopoietic stem cells (HSCs), Coeptis is also exploring improved outcomes for bone marrow transplants, offering potential breakthroughs in treating hematologic malignancies. This pioneering approach has the potential to significantly enhance patient response rates and expand the market for Coeptis' next-generation therapies. Expert Endorsement and Market Potential Dr. Evren Alici, a renowned expert from Karolinska Institutet and a member of COEP's Scientific Advisory Board, emphasized that GEAR-based immunotherapy offers a differentiated and highly promising strategy in cancer treatment. Specifically, the ability to co-administer NK cells with CD38-targeting mAbs for multiple myeloma treatment while minimizing 'on-target/off-tumor' effects could redefine how antibody-based therapies are delivered. Coeptis CEO Dave Mehalick stated, 'The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need.' Strategic Expansion with GEAR Therapeutics, Inc. To accelerate the commercialization of the GEAR platform, Coeptis has established GEAR Therapeutics, Inc., a majority-owned subsidiary dedicated to advancing GEAR-based cell therapies into human clinical trials. This move underscores Coeptis' commitment to maximizing the value of its newly acquired technology and positioning itself as a dominant player in next-generation cancer immunotherapies. Potential Investment Opportunity in COEP For investors, COEP presents a compelling growth opportunity in the rapidly evolving immunotherapy market. With exclusive rights to a novel cell therapy platform, strategic partnerships with globally recognized institutions like Karolinska Institutet, and a leadership team focused on clinical execution, Coeptis is well-positioned for long-term success. As Coeptis progresses towards clinical proof-of-concept studies for GEAR-NK, traders and investors should keep a close watch on COEP. The potential for breakthrough therapies, combined with the expanding market for immune cell therapies, makes this stock an exciting prospect in the biotechnology sector. Summary Coeptis' exclusive GEAR license signals a significant advancement in immunotherapy and a prime opportunity for investors looking to capitalize on biotech innovation. As the company continues to expand its pipeline and advance towards clinical trials, COEP's stock could become a high-value asset in the healthcare sector. Stay tuned for further developments as Coeptis transforms cancer treatment with its pioneering technologies. About VyGen-Bio, Inc. VyGen-Bio, a majority-owned subsidiary of Vycellix, Inc., operates in both Florida and Stockholm, Sweden. Its technology platforms were developed by leading researchers at Karolinska Institutet and are part of NextGenNK, an internationally recognized center for NK cell-based cancer immunotherapies. About COEPTIS, Inc. COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts. The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute. Other notable biotech stocks to keep on top of radar include (NASDAQ: VRTX) Vertex Pharmaceuticals Incorporated), (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc., (NASDAQ: ALNY) Alnylam Pharmaceuticals, Inc., (NASDAQ: RPRX) Royalty Pharma plc, (NASDAQ: SMMT) Summit Therapeutics Inc. For more details, visit Source: Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of BURU or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated five hundred dollars by a 3rd party Carriage Consulting Group for content distribution services on COEP for March 14th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: editor@ City: Frisco State: Texas Country: United States Website:
Technical.ly
08-02-2025
- Business
- Technical.ly
Pittsburgh weekly roundup: $50M for life science startups; Coeptis closes another $5.7M; Gainey vs. O'Connor on city budget
This week in Pittsburgh, a free program for young women to get their drone certifications, Abridge hires its first CFO and more. 📰 News Incubator: What else to know • More than 60 immigrant-owned and allied businesses in Pittsburgh closed Monday to take a stand against Trump's increased immigration enforcement. The closures were part of a nationwide 'Day Without Immigrants' protest. [PublicSource] • Governor Josh Shapiro shared his budget proposal Tuesday, asking the Pennsylvania legislature to legalize recreational cannabis and tax slot-like skill games to cover a spending deficit — plus, $50 million to support startups and life science companies. [SpotlightPA/Pittsburgh Biz Times] • Astrobotic secured a contract to transport California-based aerospace company Venturi Astrolab's rover to the moon aboard Astrobotic's Griffin Mission One lander. The trip is scheduled for the end of 2025. [Astrobotic] • A Carnegie Mellon student found a bug in Google Chrome's WebAssembly Code. The student donated his reward to PicoCTF, the university's annual cybersecurity competition, and Google matched the donation for a total of $462,000. [Carnegie Mellon University] • Wexford-based biopharmaceutical company Coeptis closed an additional $5.7 million in its final Series A offering, bringing the total to $10 million after an initial $4.3 million raised in June 2024. [ • Democratic mayoral candidates Ed Gainey and Corey O'Connor clashed over what projects should be funded by the city's budget during a debate Sunday. Meanwhile, several Republicans have entered the race, including Lawrenceville business owner Thomas West. [Pittsburgh City Paper/WESA] 🗓️ On the Calendar • Partner event: Take a crash course in how to think, work and build like a startup at Techstars Startup Weekend Pittsburgh from Feb. 7-9. You'll meet fellow builders, mentors, investors and more. [ Find out more ] • Enjoy an early-morning run with likeminded entrepreneurs at Pitch and Run PGH in Bakery Square on Feb. 7. [ Details here ] • Attend the 2025 Beyond Big Data: AI/Machine Learning Summit on Feb. 12 to learn how managers at every level can take advantage of the opportunities presented by artificial intelligence and machine learning. [ More info ] • Learn how to target next-round investors and secure capital on Feb. 12 as part of CMU's CONNECTS seminar series designed for students but welcome to all. [ RSVP ] • The Hardware Meetup, a global community of over 30,000 members, is hosting its first-ever meetup in Pittsburgh on Feb. 13 at the Robotics Factory. Discuss all things robots and electric vehicles with other hardware enthusiasts. [ Register ]
